ORIGINAL ARTICLE

Multicenter programme for the integrated care of newborns with perinatal hypoxic-ischaemic insult (ARAHIP) ♦, ★★★

J. Arnáez a,*, C. Vega a, A. García-Alix b, E.P. Gutiérrez c, S. Caserío d, M.P. Jiménez e, L. Castañón f, I. Esteban g, M. Hortelano h, N. Hernández i, M. Serrano j, T. Prada k, P. Diego l, F. Barbadillo m, Grupo ARAHIP ♦

a Unidad de Neonatología, Hospital Universitario de Burgos, Burgos, Spain
b Unidad de Neonatología, Hospital Sant Joan de Déu, Universidad de Barcelona, Barcelona, Spain
c Unidad de Neonatología, Hospital Universitario de Salamanca, Salamanca, Spain
d Unidad de Neonatología, Hospital Universitario Rio Hortega, Valladolid, Spain
e Unidad de Neonatología, Hospital Nuestra Señora de Sonsoles, Ávila, Spain
f Unidad de Neonatología, Hospital Universitario de León, León, Spain
g Unidad de Neonatología, Hospital San Pedro de Logroño, Logroño, Spain
h Unidad de Neonatología, Hospital General de Segovia, Segovia, Spain
i Unidad de Neonatología, Hospital General de Zamora, Zamora, Spain
j Unidad de Neonatología, Hospital Santa Bárbara, Soria, Spain
k Unidad de Neonatología, Hospital El Bierzo, Ponferrada, León, Spain
l Servicio de Pediatría, Hospital Santiago Apóstol, Miranda de Ebro, Burgos, Spain
m Servicio de Pediatría, Hospital Santos Reyes, Aranda de Duero, Burgos, Spain

Received 22 January 2014; accepted 8 May 2014
Available online 25 March 2015

KEYWORDS
Perinatal asphyxia; Hypoxic-ischaemic encephalopathy;

Abstract
Introduction: Newborns with perinatal indicators of a potential hypoxic-ischaemic event require an integrated care in order to control the aggravating factors of brain damage, and the early identification of candidates for hypothermia treatment.


This study was presented in part at the following conferences: XXIV Congreso de Neonatología y Medicina Perinatal de la Sociedad Española de Neonatología, October 2013, Barcelona. 53rd Annual Meeting of the European Society for Paediatric Research, October 2013, Porto. XXIII Congreso de Neonatología y Medicina Perinatal de la Sociedad Española de Neonatología, October 2011, Oviedo. I Reunión entre Neonatólogos de Castilla y León, November 2011, Tordesillas. Reunión Primavera de la SCCALP, April 2011, Zamora.

* Corresponding author.
E-mail address: jusoru@hotmail.com (J. Arnáez).
The ARAHIP Group is presented in Appendix A.

2341-2879/© 2014 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.
Clinical pathway; Programme

**Patients and methods:** The application of a prospective, populational programme that organises and systematises medical care during the first 6 h of life to all newborns over 35 weeks gestational age born with indicators of a perinatal hypoxic-ischaemic insult. The programme includes 12 hospitals (91 217 m\(^2\)); two level I centres, five level II centres, and five level III hospitals. The programme establishes four protocols: (a) detection of the newborn with a potential hypoxic-ischaemic insult, (b) surveillance of the neurological repercussions and other organ involvement, (c) control and treatment of complications, and (d) procedures and monitoring during transport.

**Results:** From June 2011 to June 2013, 213 of 32 325 newborns above 35 weeks gestational age met the criteria of a potential hypoxic-ischaemic insult (7.4/1000), with 92% of them being cared for following the programme specifications. Moderate–severe hypoxic-ischaemic encephalopathy was diagnosed in 33 cases (1/1000), and 31 out of the 33 received treatment with hypothermia (94%).

**Conclusions:** The programme for the Integrated Care of Newborns with Perinatal Hypoxic-Ischaemic Insult has led to providing a comprehensive care to the newborns with a suspected perinatal hypoxic-ischaemic insult. Aggravators of brain damage have been controlled, and cases of moderate–severe hypoxic-ischaemic encephalopathy have been detected, allowing the start of hypothermia treatment within the first 6 h of life. Populational programmes are fundamental to reducing the mortality and morbidity of hypoxic-ischaemic encephalopathy.

© 2014 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.

### PALABRAS CLAVE

Encefalopatía hipóxico-isquémica; Asfixia perinatal; Vía clínica; Programa

---

**Programa multicéntrico para la atención integral del recién nacido con agresión hipóxico-isquémica perinatal (ARAHIP)**

**Resumen**

**Introducción:** El recién nacido con indicadores de potencial evento hipóxico-isquémico perinatal precisa de una atención integral que detecte precozmente si necesita tratamiento con hipotermia y el control de los factores agravantes del daño cerebral en las primeras 6 h de vida.

**Pacientes y métodos:** Aplicación de un programa prospectivo de ámbito poblacional que ordena y sistematiza la atención durante las primeras 6 h de vida en los ≥ 35 semanas nacidos con indicadores de agresión hipóxico-isquémica perinatal. El programa involucra 12 hospitales (91 217 m\(^2\)), 7 de nivel asistencial i-y 5 de nivel ii. Se establecen 4 protocolos: a) detección del recién nacido con potencial agresión hipóxico-isquémica; b) vigilancia de la repercusión neurológica y en otros órganos; c) control y tratamiento de complicaciones, y d) vigilancia y acciones durante el transporte.

**Resultados:** Entre junio del 2011 y junio del 2013, de 32 325 recién nacidos ≥ 35 semanas, 213 cumplieron criterios de potencial agresión hipóxico-isquémica perinatal (7,4 por 1.000). El 92% siguió la monitorización establecida en el programa; 33 recién nacidos tuvieron encefalopatía hipóxico-isquémica moderada-grave (1 por 1.000) y 31/33 (94%) recibieron tratamiento con hipotermia.

**Conclusiones:** El programa Atención integral al Recién nacido con Agresión Hipóxico-Isquémica Perinatal ha permitido ofrecer atención integral al recién nacido con indicadores de agresión hipóxico-isquémica perinatal. Se han controlado factores comórbidos agravantes de la lesión cerebral y se han detectado aquellos con encefalopatía hipóxico-isquémica moderada-grave, permitiendo iniciar la hipotermia dentro de las primeras 6 h de vida. Programas de ámbito poblacional son cruciales para disminuir la morbimortalidad asociada a la encefalopatía hipóxico-isquémica.

© 2014 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

---

**Introduction**

The occurrence of a hypoxic-ischaemic event (perinatal asphyxia) is indicated by the presence of alterations in foetal heart rate or pH, or by the history of a sentinel episode. When this event is potentially large enough to cause tissue damage, the newborn (NB) shows neurological dysfunction (hypoxic-ischaemic encephalopathy) and/or multiple organ...
dysfunction/damage (hypoxic-ischaemic disease). Hypoxic-ischaemic encephalopathy (HIE) is the leading cause of death, severe neurological morbidity and convulsions in full-term NBs in the world, and is responsible for approximately 20% of cases of cerebral palsy in children.

Therapeutic hypothermia (targeted temperature management) is currently the specific treatment for reducing the morbidity and mortality associated with HIE. Maximum therapeutic effectiveness is obtained when it is initiated as early as possible, within the first 6 h of life. This narrow time frame means that rapid and well-organised intervention needs to be implemented within a few precious hours. This intervention protocol must establish precisely which procedures are to be performed at each stage of care: from the delivery room to intensive care, stabilisation, precise detection of the severity of HIE, checking for comorbid factors that could aggravate brain damage, and occasionally urgent transfer of the patient to referral centres that offer these NBs integrated care including hypothermia.

In order to establish an organised intervention protocol aimed at early detection of NBs with HIE who need treatment with hypothermia and at correcting and avoiding factors that aggravate brain damage in the first 6 h of life, a population-based programme, Integrated Care of Newborns with Perinatal Hypoxic-Ischaemic Insult (Atención Integral al Recién nacido con Agresión Hipóxico-Isquémica Perinatal [ARAHIP]) has been developed, involving 12 hospitals in the regions of Castilla y León and La Rioja. We here present the programme and report on the experience of the first 2 years of its operation (June 2011–June 2013).

**Methodology**

**Steps followed in formulating the programme**

1. Development of the draft text and preparation of the case report form.
2. Analysis of the real possibilities of applying the programme for each centre and appointment of coordinators.
3. Visit to the centres; presentation of the programme and delivery of the material (programme, summary posters/protocols, training video on neurological examination, case report form).
4. Follow-up of the development of the programme once initiated, difficulties, meeting of coordinators.

**Hospitals included and their characteristics**

Hospitals participating in the ARAHIP programme: (a) Hospital Universitario, Burgos (coordinating centre); (b) Hospital Universitario Rio Hortega, Valladolid; (c) Hospital Universitario, Salamanca; (d) Hospital San Pedro, Logroño; (e) Hospital Nuestra Señora de Sonsoles, Ávila; (f) Hospital Universitario, León; (g) Hospital General, Segovia; (h) Hospital Santa Bárbara, Soria; (i) Hospital General, Zamora; (j) Hospital El Bierzo, Ponferrada; (k) Hospital Santiago Apóstol, Miranda de Ebro, and (l) Hospital Santos Reyes, Aranda de Duero.

The number of live NBs greater than 35 weeks gestation cared for in these hospitals put together is approximately 16,000 per year. In all of them the NBs are attended at birth by a midwife, with the support of the paediatrician in the event of any associated abnormality. As regards the health care level of the hospitals, two of them are level I, five are level II and five are level III. In all, a total of 168 paediatricians (66 of them residents), participating in attending deliveries and in neonatal care, were involved in the programme.

**Clinical pathway developed in the programme**

(Figs. 1–4)

Every NB greater than 35 weeks gestation and greater than 1800 g at risk of having suffered a perinatal hypoxic-ischaemic insult is included in the programme (Fig. 1). This was defined as meeting at least one of the following criteria: (a) umbilical cord pH of 7.00 or less; (b) Apgar score at 5 min of 5 or less, and (c) need for resuscitation with intubation and/or heart massage or need for intermittent positive pressure at 5 min. Other supporting but not mandatory criteria for including NBs in the programme were: (a) non-reassuring foetal status (sustained bradycardia, late decelerations or meconium-stained amniotic fluid); (b) existence of a sentinel hypoxic event (placental detachment, umbilical cord prolapse, uterine rupture, foetal exsanguination in the mother), and (c) obstructed labour.

All the NBs that meet the inclusion criteria are enrolled (Fig. 2). The object of enrolment is two-fold: (1) early detection of the presence of moderate or severe HIE and (2) control of factors that could aggravate brain injury or its complications (Fig. 3). To achieve the first objective, systematic neurological examinations are performed at 1, 3 and 5 h after birth, and the severity of HIE is established according to the scale proposed by García-Alix et al. Hospitals equipped with amplitude-integrated electroencephalography initiate electrocortical monitoring immediately after enrolment and this is maintained until at least 6 h after birth or until the tracing normalises (normal voltage, presence of sleep-wake cycling and absence of seizures) If the NB shows moderate/severe HIE in any of the examinations, the receiving referral hospital is contacted for transfer and hypothermia treatment. The area covered by the programme has no established specialised neonatal transport service, so specific instructions have been laid down for managing these children during transfer (Fig. 4).

For the second objective, control of comorbid factors (temperature, hypoglycaemia, hypocarbia, hypomagnesaemia, etc.) with the potential to aggravate brain damage is done by clinical and analytical monitoring (Fig. 2). The management and specific treatment of these comorbid factors are standardised (Fig. 3).

Informed consent is requested from parents in the programme so as to be able to analyse the clinical information derived from it, and it has been approved by the Research Ethics Committee of the coordinating hospital.

**Results**

The ARAHIP population-based programme includes an extensive group of health care facilities with a total area of 91,217 m². During the 2 years the programme lasted there
**NEWBORN AT RISK OF DEVELOPING HYPOXIC-ISCHAEMIC DISEASE**

- **Paediatrician called to the delivery room because of**
  - **DATA CONSISTENT WITH A PERIPARTUM HYPOXIA-ISCHAEMIA SITUATION**
    - Non-reassuring foetal status in foetal monitoring: sustained bradycardia, late decelerations, meconium-stained amniotic fluid...
    - Existence of a sentinel hypoxic event (placental detachment, umbilical cord prolapse, uterine rupture…)
    - Obstructed labour

- **OTHER REASONS:**
  - elective caesarean, IUGR, ruptured membrane, risk of early-onset sepsis…

**LABOUR**

1. Advanced resuscitation: positive pressure (>5 min), intubation, heart massage, medication
   - Apgar at 5’ ≤ 5
   - No need for advanced resuscitation

   - Switch off radiant heating
   - Minimum FiO2 for 92–94% preductal SaO2
   - Avoid volume expansion
   - Avoid bicarbonate
   - Switch off transport incubator
   - Take rectal temp.: avoid <34 ºC and >36 ºC

2. Watch for reduction in wakefulness (lethargy, stupor, coma)
   - Level of alertness
   - Tone, movement, respiration
   - Assess:
     - No admission

**ADMISSION TO NEONATAL UNIT**

- Haemodynamic and respiratory stabilisation
- Place aEEG electrodes
- Check inclusion and exclusion criteria. Deliver Information Sheet
- CONTACT hypothermia receiving hospital

**TRANSFERS**

- Request umbilical cord pH

- ≤ 7.00
- > 7.00
  - Altered
  - Normal

**FIRST 6 HOURS OF LIFE**

- Place the NB in a warming bed (heat off)
- Monitor core (rectal) temp. q15 min
- Monitor 
- Haemodynamic and respiratory stabilisation
- Place aEEG electrodes
- Check inclusion and exclusion criteria. Deliver Information Sheet
- CONTACT hypothermia receiving hospital

**OBJECTIVES IN THE FIRST 6 HOURS**

1. Stabilisation of vital signs
2. Watch for reduction in wakefulness (lethargy, stupor, coma)
3. Avoid factors that could aggravate brain damage (hyperthermia, hypocarbia, hypoglycaemia, hypocalcaemia, hypomagnesaemia, etc.)

**WATCH FOR SIGNS OF HYPOXIC-ISCHAEMIC DISEASE**

Clinical and analytical monitoring according to PROTOCOL

**IF MODERATE OR SEVERE ENCEPHALOPATHY, MAINTAIN TEMPERATURE AT 33.5–34 ºC**

**ACTIVATE TRANSPORT TO RECEIVING HOSPITAL WITH HYPOTHERMIA**

Newborns who meet criteria for hypoxic-ischaemic insult are those that present with any of the conditions numbered 1, 2, 3 highlighted in the boxes with an orange background.

IUGR: intrauterine growth retardation, min: minute(s), temperature, aEEG: amplitude-integrated electroencephalogram

**Figure 1** Inclusion in the programme of newborns with a potential perinatal hypoxic-ischaemic insult.
**Programme for Integrated Care of Newborns with Perinatal Hypoxic-Ischaemic Insult**

NEWBORNS MEETING CRITERIA FOR PERINATAL HYPOXIC-ISCHAEMIC INSULT
MONITORING AND SURVEILLANCE OF ENCEPHALOPATHY AND MULTISYSTEMIC INVOLVEMENT

<table>
<thead>
<tr>
<th>First hour</th>
<th>3 hours</th>
<th>5 hours</th>
<th>12 hours</th>
<th>24 hours</th>
<th>48 h</th>
<th>72 h</th>
<th>7–14 days</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No HIE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral line</td>
<td>Blood gases</td>
<td>Blood gases</td>
<td>Same if previous results show pathology</td>
<td>DISCHARGE if</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glycaemia</td>
<td>Glycaemia</td>
<td></td>
<td>• Recovered from acidosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grading (scale)</td>
<td>Grading (scale)</td>
<td></td>
<td>• Clinical status satisfactory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• No factors that could aggravate brain damage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amplitude-integrated EEG (aEEG)</td>
<td></td>
<td></td>
<td>Withdraw aEEG at 6 hours after birth if tracing normal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mild HIE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral line</td>
<td>Blood gases</td>
<td>Blood gases</td>
<td>Blood gases</td>
<td>Blood gases</td>
<td>If previous results show alteration</td>
<td>DISCHARGE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glycaemia</td>
<td>Glycaemia</td>
<td>Glycaemia</td>
<td>Glycaemia</td>
<td>Biochemistry</td>
<td>Biochemistry</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grading (scale)</td>
<td>Grading (scale)</td>
<td>Grading (scale)</td>
<td>Grading (scale)</td>
<td>Urine</td>
<td>Urine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amplitude-integrated EEG (aEEG)</td>
<td></td>
<td></td>
<td>Withdraw aEEG at 6 hours after birth if tracing normal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain scan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>** Moderate or severe HIE (1)**</td>
<td>Blood gases</td>
<td>Blood gases + glycaemia</td>
<td>Blood count</td>
<td>Blood culture</td>
<td>PROTOCOL OF RECEIVING HOSPITAL WITH HYPOTHERMIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central line</td>
<td>Glycaemia</td>
<td>Blood count</td>
<td>Biochemistry</td>
<td>Blood culture</td>
<td>Blood gases</td>
<td>Glycaemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grading (scale)</td>
<td>Grading (scale)</td>
<td>Grading (scale)</td>
<td>Grading (scale)</td>
<td>Glycaemia</td>
<td>Glycaemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amplitude-integrated EEG (aEEG)</td>
<td></td>
<td></td>
<td></td>
<td>Serial + doppler scans</td>
<td>MRI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brain scan (preferably in the first 6 hours of life)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) In this case the lab tests must be done as soon as the severity of the HIE is established as moderate or severe. Until that point the same tests must be performed as in the other situations.

**Definitions:**
- **Scale:** the agreed scale in García-Alix A (Pediatrics 1994) for classifying HIE as mild / moderate / severe will be used.
- **Biochemistry:** Na, K, Cl, Ca, Mg, GOT, GPT, total protein, albumin, creatinine, total and direct bilirubin, CK, CK-MB, troponin I, ammonium and cortisol.
- **Coagulation:** prothrombin time, cephalin time, INR, D-dimer, fibrinogen.
- **Urine:** pH, density, protein, Na, K, Cl, creatinine, osmolality.

**Figure 2** Monitoring of neurological repercussions of hypoxic-ischaemic insult and other organ involvement.
### Programme for Integrated Care of Newborns with Perinatal Hypoxic-Ischaemic Insult

#### NEWBORNS MEETING CRITERIA FOR PERINATAL HYPOXIC-ISCHAEMIC INSULT

**PROCEDURES IN THE FIRST 6 HOURS OF LIFE**

<table>
<thead>
<tr>
<th>Neurological: Encephalopathy</th>
<th>1.- Clinical presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Neurological examination, classification of the degree of encephalopathy (scale).</td>
</tr>
<tr>
<td></td>
<td>• Avoid hyperthermia: maintain temp. at 34.5–36 °C until decision to initiate hypothermia or not. Avoid fluctuations.</td>
</tr>
<tr>
<td></td>
<td>• Treat convulsions.</td>
</tr>
<tr>
<td></td>
<td>1. -1st line: phenobarbital. Loading dose: 20 mg/kg/dose; if no relief in 10 min: bolus of 10 mg/kg (max. total 30 mg/kg).</td>
</tr>
<tr>
<td></td>
<td>2. - Amplitude-integrated EEG. From admission</td>
</tr>
<tr>
<td></td>
<td>• Identify type of tracing and seizures. If the latter are present, treat them.</td>
</tr>
<tr>
<td></td>
<td>• Monitoring to be maintained during first 6 h of life or longer until tracing is normal.</td>
</tr>
<tr>
<td></td>
<td>4. INVOS: To be monitored, if available, in infants with significant neurological symptoms (moderate or severe HIE).</td>
</tr>
</tbody>
</table>

If the clinical presentation shows moderate or severe encephalopathy, hypothermia treatment is to be initiated! aEEG is not an inclusion criterion, but if there is a discrepancy with the clinical picture, the reasons must be investigated.

<table>
<thead>
<tr>
<th>Respiratory: Ventilation and oxygenation</th>
<th>1.- Blood gas analyses according to timeline (enter patient’s core temp. in the autoanalyser).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- FiO2 for 92-94% preductal sat. Watch out for pulmonary hypertension.</td>
</tr>
<tr>
<td></td>
<td>3.- Monitor breathing pattern (central neurogenic hyperventilation, paradoxical breathing, gasping…).</td>
</tr>
<tr>
<td></td>
<td>4.- If intubation is needed, avoid hypocarbia (target 40–50 mmHg) using partial support modes (SIMV + VG) with low respiratory rates, increasing the dead space (spacing chamber) if necessary.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiovascular</th>
<th>1.- Vital signs with BP qhr. Monitor heart rate, blood pressure and electrocardiogram.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- Avoid volume expansion, especially abrupt. Individualise treatment if there is myocardial dysfunction and persistent acidosis / extracranial haemorrhage.</td>
</tr>
<tr>
<td></td>
<td>3.- Sinus bradycardia is common. EKG must be monitored to detect signs of myocardial ischaemia.</td>
</tr>
<tr>
<td></td>
<td>4.- If there are signs of myocardial dysfunction, perform heart scan and consider using inotropic drugs (dobutamine&gt; dopamine&gt;adrenalin). Ensure cerebral perfusion (INVOS, mixed venous saturation…) and try not to increase the afterload.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Renal</th>
<th>1.- Check diuresis (weigh nappies). Bladder intubation is advisable if there is encephalopathy.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- Urinalysis. Detect kidney damage: proteinuria, ion loss, low density…</td>
</tr>
<tr>
<td></td>
<td>3.- Administer single dose of aminoglycoside until adequate diuresis is confirmed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gastrointestinal</th>
<th>1.- If gastric pH is &lt;4 or there are blood traces, use ranitidine.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- Keep on diet at least 6–8 h, depending on clinical status and gradual correction of acidosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hepatic</th>
<th>1.- Monitor transaminases, prothrombin T, cephalin T, fibrinogen, albumin, bilirubin and ammonium in serum.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- Keep on diet at least 6–8 h, depending on clinical status and gradual correction of acidosis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Haematological</th>
<th>1.- Detect signs of bleeding (gastric, urine, puncture sites…). Lab test: platelets and coagulation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- If &lt;50,000 plt: transfuse platelets.</td>
</tr>
<tr>
<td></td>
<td>3.- If there is coagulopathy (PT&lt;40%, INR &gt;2,Cefalin T&gt;50s, fibrinogen &lt;100): vit K 1 mg iv and FFC 10 mL/kg.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Haemostatic</th>
<th>Platelets Prothrombin T Cephalin T D-dimer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIC</td>
<td>↓ Normal Normal Normal</td>
</tr>
<tr>
<td>Endothelial damage</td>
<td>↓ Normal Normal</td>
</tr>
<tr>
<td>Liver damage</td>
<td>Normal ↑ Normal ↑ Normal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hydroelectrolytic homeostasis</th>
<th>1.- Request blood glucose test according to timeline. If BGL &lt;70 mg/dL, initiate dextrose infusion. If &lt;50, administer an initial 2 mL/kg bolus of 10% dextrose solution with a continuous infusion, at a slow rate, over 5–10 min.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- Serum therapy with doses limited to 40-50 mL/kg. Use central line if more concentrated glucose solutions needed (12, 15 and 20%).</td>
</tr>
<tr>
<td></td>
<td>3.- If total Calcium &lt;8 mg/dL /ionic &lt;1 mmol/L: increase calcium in serum. Avoid boluses.</td>
</tr>
<tr>
<td></td>
<td>4.- According to Magnesium levels, see table.</td>
</tr>
<tr>
<td></td>
<td>5.- Avoid bicarbonate because of paradoxical alkalosis with tissue acidosis. Allow gradual correction.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mg serum levels</th>
<th>Treatment</th>
<th>15% Mg sulphate solution (1 mL/150 mg) IV or IM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2–1.6 mg/dL</td>
<td>25–50 mg/kg</td>
<td>IV: 0.4 cc/kg/dose (50 mg/kg/dose half &amp; half with distilled water, slow IV (2–3 min)</td>
</tr>
<tr>
<td>&lt;1.2 mg/dL</td>
<td>50–100 mg/kg</td>
<td>IM: if volume exceeds 0.6 cc divide dose between both thighs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sedoanalgesia</th>
<th>1.- Sedative drugs (fentanyl, midazolam, phenobarbital) must be avoided until the decision to initiate hypothermia.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.- Once the HIE has been classified as moderate or severe and cooling initiated, avoid stress (frowning, tightly clenched fists, irritability, HR &gt;120 bpm…). Use fentanyl or morphine at half usual dose.</td>
</tr>
</tbody>
</table>

BGL: blood glucose level, DIC: disseminated intravascular coagulation, FFC: fresh frozen plasma, HR: heart rate, q: each

---

**Figure 3** Control and treatment of complications.
Newborns (NBs) with moderate/severe hypoxic-ischaemic encephalopathy are those with a history of ischaemia and/or hypoxia around birth and clinical manifestations in the central nervous system such as diminished awareness, hypotonia, convulsions, poor respiratory effort, etc.

Monitoring of complications (hypoglycaemia, hyperthermia, etc.) and moderate hypothermia treatment (temp. 33–34 ºC) initiated within the first 6 hours of life have proved effective for increasing survival and reducing long-term neurological disability.

Given the narrow time frame (less than 6 hours) for initiating treatment, prompt transfer with appropriate monitoring, avoiding temperature fluctuations, is essential. In most cases treatment will be initiated in the sending hospital, and it is crucial that the patient is transferred to the receiving hospital with a rectal temperature of 33–34 ºC. If the NB is brought to this temperature and it is maintained for the first 6 hours of life, the receiving hospital can continue the treatment even if it receives the infant after the 6 hours have elapsed.

RECOMMENDATIONS DURING TRANSFER:

- **Temperature.** It is vital to maintain temperature stable throughout the whole transfer, without fluctuations ± 0.5 ºC.
  - Important!: the following situations must be distinguished:
    1. NB is already included in hypothermia programme (initiated at sending hospital).
       - Objective: maintain rectal temperature at a constant level of 33.5–34ºC.
    2. NB is candidate for evaluation at the receiving hospital.
       - Objective: maintain core (rectal) temperature at the same level as when the NB leaves the sending hospital. Never below 34 ºC nor above 36.5 ºC.

If in doubt as to whether it is a nb with moderate/severe hie, follow procedure for situation 1.

- **Respiration.** Perform blood gas analysis and agree with the sending hospital before transfer on the most suitable respirator parameters to maintain a pCO2 of 40–45 mmHg and the minimum FiO2 for O2 saturation of 92–94%.

- **Haemodynamics.** Maintain mean blood pressure above 40 mmHg. The heart rate of asphyctic NBs, especially those undergoing hypothermia, is normally between 90 and 220 bpm. If volume expansion and/or inotropic drugs are needed consult the receiving hospital to agree on the most suitable treatment, given that as a general rule one should try to avoid expansions.

- **Glycaemia.** Measure capillary blood glucose before transfer and also, if possible, during transfer. If BGL <50 mg/dL, administer a 2 mL/kg/dose bolus of 10% dextrose solution, diluted half & half, over 5 min. During transfer, maintain total liquid administration at 50–60 mL/kg/24 hours with 10% glucose solution (modify concentration according to blood glucose levels).

- **Sedoanalgesia.** If cooling has not yet been initiated and there are reasonable doubts about whether moderate/severe HIE is involved, drugs that interfere with the clinical assessment of encephalopathy (sedatives, relaxants, anticonvulsants) must be avoided. However, in patients that may have moderate/severe HIE it is essential to avoid stress (crying, discomfort…), and especially if hypothermia has been initiated, with fentanyl 1 mcg/kg/dose (infuse very slowly over 5–10 min). Morphine 0.1 mg/kg/dose can also be used in intravenous boluses.

If any doubt arises during transfer, contact ___________ hospital:

Telephone: Direct line (S): __________ Switchboard: __________

Figure 4 Monitoring and procedures during transport to the receiving hospital.
were 32,325 deliveries of NBs greater than 35 weeks gestation and greater than 1800 g. Fig. 5 gives details of the NBs included in the ARAHIP programme and Table 1 shows their main characteristics. Nine of the 12 centres routinely performed cord blood gas analysis for all births. In the remaining three (7636 NBs), blood gas analysis was carried out at the discretion of the physician attending the delivery, in most cases because of perinatal respiratory depression. Taking the 12 participating hospitals as a whole, 213 live NBs met the criteria for perinatal hypoxic-ischaemic insult. This represents a total incidence of 6.6 per thousand live births (95% CI, 5.7–7.5), which, if we exclude the three hospitals without routine pH measurement, increases slightly to 7.4 per 1000 live births (183/24,689; 95% CI, 6.3–8.6). Of the 213 BNs with criteria, 64 showed HIE in the first 6 h of life (2 per 1000 live births; 95% CI, 1.5–2.5): 31 mild, 23 moderate and 10 severe. The incidence of moderate/severe HIE was one per 1000 (95% CI, 0.7–1.4).

Of the 33 NBs with moderate/severe HIE, 31 were treated with hypothermia (94%). Two were not, for the following reasons: in one case the grading of HIE was not carried out in time and in another the patient was not transferred because of instability secondary to severe pulmonary hypertension. Nine (9/31, 29%) were not transferred because they were born in one of the two hospitals with therapeutic hypothermia. Of the 22 that were transferred, 17 (77.3%) reached the receiving hospital within the first 6 h of life, with a median of 5 h (IQR, 1 h). Passive hypothermia was initiated in all the NBs in their sending hospital; the mean temperature of the transferred infants on arrival at the receiving hospital was 33.1 ± 1.2 °C (range, 29–34.9 °C). In the five NBs who reached the receiving hospital more than 6 h after birth, the treatment was maintained, because hypothermia was initiated at their sending hospital within the 6 h.

Ten infants (10/33; 30.3%) died during the programme. In 7/10 cases this was mainly related to the severity of the HIE, and of the remaining three one had a ruptured bowel,

Table 1 General characteristics of the 213 newborns included in the programme.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value (n=213)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age, mean ± SD (weeks)</td>
<td>39.1 ± 1.7</td>
</tr>
<tr>
<td>Birth weight, mean ± SD (g)</td>
<td>3133 ± 537</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>114/211 (54)</td>
</tr>
<tr>
<td>Sentinel event, n (%)</td>
<td>22/210 (10)</td>
</tr>
<tr>
<td>Full-term delivery, n (%)</td>
<td>69/212 (33)</td>
</tr>
<tr>
<td>Instrumental labour, n (%)</td>
<td>68/212 (32)</td>
</tr>
<tr>
<td>Caesarean, n (%)</td>
<td>72/212 (34)</td>
</tr>
<tr>
<td>Apgar at 5 min &lt;5, n (%)</td>
<td>40/210 (19)</td>
</tr>
<tr>
<td>Apgar at 10 min &lt;5, n (%)</td>
<td>16/134 (12)</td>
</tr>
<tr>
<td>Meconium-stained amniotic fluid, n (%)</td>
<td>75/202 (37)</td>
</tr>
<tr>
<td>Advanced resuscitation, n (%)</td>
<td>73/210 (35)</td>
</tr>
<tr>
<td>Umbilical cord pH ≤ 7, n (%)</td>
<td>111/156 (71)</td>
</tr>
<tr>
<td>Moderate or severe HIE in first 6 h of life, n (%)</td>
<td>33/213 (15)</td>
</tr>
<tr>
<td>Hypothermia treatment n (%)</td>
<td>31/33 (94)</td>
</tr>
<tr>
<td>Extramural hypothermia treatment, n (%)</td>
<td>22/31 (71)</td>
</tr>
</tbody>
</table>

* Advanced resuscitation: intermittent positive pressure, intubation, medication and/or heart massage.
due to traumatic delivery, in addition to HIE, another had complex congenital heart disease and the third died from a neuromuscular disease.

Discussion

Neonatal encephalopathy due to perinatal hypoxic-ischaemic insult causes high neonatal morbidity and mortality in NBs greater than 35 weeks gestation, and those that survive the neonatal period have a high risk of serious and permanent lifelong consequences. Total body cooling or selective head cooling has proved to be an effective and safe therapeutic intervention for reducing mortality and major disability in survivors. Maximum therapeutic effectiveness is obtained when it is initiated as early as possible, and always within the first 6 h of life.

Various conditions reduce the likelihood of appropriate care being provided in these first hours and of therapeutic hypothermia treatment being initiated in this narrow time frame. The most important of these are the following: (a) most newborns who develop HIE are born in hospitals with no neonatal intensive care unit or established hypothermia programme; (b) identifying the severity of HIE in these first hours of life is not easy and requires experience and clinical training; (c) certain comorbid conditions that can aggravate brain damage during those first hours need to be monitored, and (d) if the patient needs to be transported to a hospital with a hypothermia programme, this must be done urgently and under strict control.

This is why it is argued that a rapid and well-organised plan of action needs to be established within a few precious hours. To achieve this requires developing programmes that involve joint action between levels I and II neonatal units and medical emergency coordination centres (transport teams) with level III units, which offer integrated care, including hypothermia, for NBs with HIE. This joint plan of action of centres at various health care levels with transport services has been called the "hypothermia code".

The ARAHIP programme was designed specifically to establish this "hypothermia code", and thereby organise and systematise care of NBs with perinatal hypoxic-ischaemic insult on a coherent basis. The programme sought, above all, to provide and safeguard the care these NBs need, and to reduce delays in initiating hypothermia treatment. One of its strengths is that it involves an extensive area of health care facilities (approximately 91 000 m²) and 12 hospitals, with neonatal units at various health care levels.

Although specific recommendations and programmes in the area of hypothermia treatment do exist, it is not easy to find protocols or clinical pathways that organise the whole process of the care of NBs at risk of developing HIE before therapeutic hypothermia is initiated. Hypothermia treatment needs to be strictly conducted in clinical practice in order to optimise its success outside clinical trials, and similar strictness is also required in prior monitoring and appropriate selection of candidates for receiving this treatment. In Spain, protocols have been developed at hospital level for the care of BNs during hypothermia treatment, but as far as we know the only existing programme similar to ARAHIP is the Hipocat programme in Catalonia. The ARAHIP programme, however, also offers a specific clinical pathway for the care, selection and early identification of NBs with hypoxic-ischaemic insult from birth in a large population area.

The incidence of one per 1000 live NBs detected in the programme is practically double that reported in two tertiary hospitals in Spain, one in Madrid and another in Barcelona. Our programme used the same definition of HIE and the same grading system as these hospitals, but our incidence is population-based, and therefore it is not limited to level III hospitals but has the virtue of including centres at different health care levels and a diverse range of hospitals, illustrated by the fact that only one of the centres has a neonatal service operating 24 h a day. On the other hand, although there was only one case in which the severity of the encephalopathy was not correctly identified within the window period, it is quite possible that without the monitoring undertaken as part of the programme this number would have been higher. This highlights the need to establish monitoring programmes, training the professionals who attend deliveries to recognise HIE and the possible need for therapeutic hypothermia treatment. If we want to offer high quality care programmes delivered by expert teams with the appropriate technological means, it is essential to focus resources and rationalise the development of hypothermia programmes, which means that patients and programmes have to be centralised in the tertiary hospitals in each geographical area. The ARAHIP programme has not received any specific institutional support and it arose exclusively from collaboration and agreement among the professionals caring for these children.

Another of the programme’s basic principles was checking for aggravating factors and for complications associated with hypoxic-ischaemic insult during the first 6 h after birth. Although the programme does not address the management of neonates during the period of therapeutic hypothermia, it is very similar in the two hospitals that offer this therapy.

One of the limitations of the ARAHIP programme is the non-availability of a specialised transport service, although the programme itself made it possible to limit the consequences of this deficiency. One of the main obstacles to therapeutic success is arrival at the receiving hospital without hypothermia and outside the window period. The NBs in the ARAHIP programme reached the receiving hospital at a median of 5 h and 91% of them with a temperature of around 34 °C, which to a certain extent reflects the success of the programme. However, although the median temperature on arrival at the receiving hospital was 33.1 °C, in 50% of cases it was below 33 °C. Although the overcooling was slight, it can occur with passive hypothermia during transport, and our data are consistent with those reported in regions of similar size in other countries. Many of these regions have specialised transport, as well as servo-controlled cooling equipment, a preferable system for maintaining a stable temperature. In Spain, autonomous communities such as Madrid and Catalonia have trained teams with protocols for managing NBs with HIE during transport. The ARAHIP programme has made it possible, through systematic monitoring of every NB at risk of HIE and application of recommendations for transfer formulated as a protocol, to achieve a high rate of
hypothermia treatment in the window period, initiated at the sending hospital and maintained during transfer.\textsuperscript{17,16} The excellent communications between the sending and receiving hospitals, with the support of the transport teams, has been a key factor in achieving these results. The fact that the NB is sometimes transferred by a neonatologist from the sending hospital may also have played an important role.

To sum up, the ARAHIP programme has made it possible to offer integrated care to NBs with possible perinatal hypoxic-ischaemic insult in the first hours of life by following a clinical pathway that includes specific protocols aimed at early identification of those with HIE, checking for factors that could aggravate brain injury, urgent transfer to a hospital with a therapeutic hypothermia programme and initiation of hypothermia within the time frame of the first 6h of life. Increasing experience among the professionals caring for these children, extended to as high a proportion of health care centres as possible, can only contribute to ensuring that these patients are offered the best care.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgements

To Dr Amaia Cilla, for her contributions to the writing of the manuscript.

To the paediatric residents and nurses in the neonatal units, for their active involvement in carrying out the programme.

Appendix A. The ARAHIP Group

- Hospital Universitario, Burgos: María Miranda, Carmen Bustamante, Susana Schuffelmann, Cristina de Frutos and Joaquín Suárez.
- Hospital Santa Bárbara, Soria: Ruth Romero and Ana Peña.
- Hospital General, Segovia: Santiago Calleja.
- Hospital Nuestra Señora de Sansoles, Ávila: Felipe Rubio, Ana María Jiménez, Manuel Felipe Marrero, Antonio Javier Martín and Sara Rupérez.
- Hospital Universitario, León: Daniel Mata, María Fernández and Lara García.
- Hospital Universitario, Salamanca: Ana Belén Remesal and Rubén García.
- Hospital General, Zamora: Víctor Manuel Marugán.
- Hospital El Bierzo, Ponferrada: Rosario Velasco.
- Hospital Universitario Río Hortega, Valladolid: Sara Marín, Mar Montejo, Carla Escribano, Raquel Izquierdo, Elena Infante and María Samaniego.
- Hospital Santiago Apóstol, Miranda de Ebro: Ana Vereas.
- Hospital San Pedro, Logroño: María Beatriz Fernández and María Yolanda Ruiz.

References


